Pathos AI Completes Acquisition of Rain Oncology

Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights CHICAGO–(BUSINESS WIRE)–Pathos AI, Inc. (www.pathos.com), today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc.